Products

Fast results. More answers. Better patient outcomes.

Great Basin’s sample-to-result molecular diagnostics can provide several key advantages over other molecular and non-molecular solutions:

  • Fully automated, true sample-to-result system with few hands-on steps that do not require special staffing to read results
  • Low upfront analyzer cost, and cost-competitive assay pricing
  • Results in about 90 minutes, and on-demand testing (no batching of tests!) means faster time to treatment
  • Low-plex and multiplex testing on the same system means saved benchspace and simplicity for your techs

PANELS AND TESTS

Easy-to-use. Sample-to-Result. Cost-effective.

Great Basin’s breakthrough approach to molecular diagnostics provides fast, cost-effective diagnosis of infectious diseases. Our easy-to-use assays deliver more diagnostic data per sample, meaning healthcare providers are able to treat patients with the right medication sooner, improving outcomes and reducing costs.

Learn More

THE SYSTEM

Clear Treatment Path. Huge Time-Savings.

Great Basin’s diagnostic system provides the answers health care providers need to rule out possible causes and define a clear treatment path which means a huge time-savings for a strained healthcare system and quicker recovery for patients.

Learn More

ANTIMICROBIAL STEWARDSHIP

Expedite time to optimal therapy leading to reduced antibiotic resistance, reduced costs and improved patient outcomes

The CDC estimates that there are 47 million unnecessary prescriptions for antibiotics written each year in the U.S., and that over 10 million Americans will die from untreatable superbugs by 2050.

Learn More

Learn more about how Great Basin’s sample-to-result system can help your hospital or lab make fast and accurate molecular diagnostics possible.

In the News

Great Basin and Rice University Announce Collaboration to Optimize the Design of SARS-CoV-2 Molecular Assays
August 25, 2020

Salt Lake City, Utah, and Houston, Texas – August 25, 2020 (PRWeb) – Great Basin Scientific, a [...]

Vela Diagnostics Submitting Novel Coronavirus Diagnostic Test to FDA for Emergency Use Authorization (UPDATE)
February 11, 2020

Singapore, February 11, 2020 (updated on February 21, 2020) – Vela Diagnostics has developed the [...]

Vela Diagnostics Announces Development of New Test Kit for Detection of Wuhan Coronavirus
January 31, 2020

Singapore, January 30, 2020 – Vela Diagnostics has announced the development of the ViroKeyTM SA201 2019-nCoV [...]

Vela Diagnostics Buys Great Basin Scientific
June 21, 2018

Adds 6 FDA Approved Products on a Medium Multiplexing Platform and Microbiology Know-how Enabling our [...]

Stool Bacterial Pathogens Panel Receives FDA Clearance; Commercial Rollout Begins Immediately
July 13, 2017

At clearance, Company has nearly $2.0 million of potential annual revenue in active or scheduled [...]

Data Demonstrating Efficacy of Stool Bacterial Pathogens Panel Presented at ASM Microbe 2017
June 1, 2017

Four posters describing the Company’s platform to be presented, including a third-party clinical study poster [...]

Bordetella Direct Test Receives FDA Clearance
April 3, 2017

Sample-to-result test for Bordetella pertussis, or whooping cough, receives clearance in fewer than 60 days from [...]

Great Basin Staph ID/R Blood Culture Panel Clinical Evaluation Published in Journal of Clinical Microbiology
February 15, 2017

Multicenter evaluation demonstrates Staph ID/R Blood Culture Panel’s efficacy in rapid identification of Staphylococci and [...]

View More